FRI0108 Risk for herpes zoster after treatment with biologic and synthetic disease modifying agents for rheumatoid arthritis
Identifieur interne : 001216 ( Main/Exploration ); précédent : 001215; suivant : 001217FRI0108 Risk for herpes zoster after treatment with biologic and synthetic disease modifying agents for rheumatoid arthritis
Auteurs : D. A. Pappas [États-Unis] ; M. Hooper ; G. Reed ; Y. Shan ; D. Wenkert ; J. Zhang [Royaume-Uni] ; J. Greenberg [États-Unis] ; J. Curtis [Royaume-Uni]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
- Additional confounders, Amgen, Biologic, Brosis, Cardiovascular, Cardiovascular disease, Cholesterol levels, Cohort, Corrona, Corrona registry, Crescendo bioscience, Echographic, Expert physician, Herpes zoster, Hrct, Hrct scores, Lung ultrasound, Nbio, Nijmegen, Ntnfi, Ntnfi cohort, Propensity, Propensity score, Rheumatoid, Rheumatoid arthritis, Serum samples, Tnfi, Tnfi cohort, Total number.
Abstract
Background Herpes zoster (HZ) is an opportunistic infection with a high incidence in Rheumatoid Arthritis (RA) patients. There are contradictory data regarding the risk of HZ associated with treatment with biologic and non biologic disease modifying agents (DMARD). Objectives To compared the risk for HZ among new users of TNF inhibitors (TNFi), non-TNF inhibitor biologics (nTNFi) and non biologic DMARD (nBIO) in RA patients participating in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Methods The CORRONA registry is a network of rheumatology practices across the U.S. with patient and physician derived data on more than 27,000 RA patients. Patients with or without background methotrexate were categorized to three treatment cohorts (TNFi vs nTNFi vs nBIO). Follow-up time began with initiation of a TNFi; a nTNFi; or Leflunomide, sulfasalazine, or hydroxychloroquine (nBIO cohort). Exposure was considered “as treated” and analyses were censored if patients switched treatment groups and after the 1st HZ event. HZ events were based on physician report. Patients with a history of HZ were excluded (analysis without their exclusion yielded similar results). Propensity scores (PS) were created using multinomial logistic regression, and the PS included age, gender, prednisone use, mHAQ, CDAI, duration of RA, Rheumatoid factor positivity (RF+), history of diabetes mellitus (DM) cardiovascular disease (CVD) and cancer (Ca). Stratification on propensity score quintile was conducted and hazard ratios (HR) were estimated using Cox regression to examine the risk of HZ associated with each treatment. Any factors in imbalance within stratified quintiles were examined as additional confounders. In a separate analysis, three way propensity score matching of nBIO, TNFi, and nTNFi biologic (1:2:1) was performed with a propensity score using age, gender, prednisone treatment (tx), mHAQ, duration of RA, and RF+. Results The propensity stratified analysis included 2,809 in the TNFi cohort, 1,182 in the nTNFi cohort and 1,070 in the nBIO 842 cohort. At baseline: the nTNFi cohort included more females, patients with longer RA duration, more frequent RF+ and steroid tx, higher mHAQ, and CDAI. The TNF cohort included younger patients with fewer comorbidities (DM, Ca, CVD). The overall rate of HZ was 8/1000 person yrs [95%CI: 7, 11]. Using the TNFi cohort as the referent group the hazard ratio for nBIO was 0.97 (95%CI:0.54-1.77, p=0.93) and for nTNFi was 0.81 (95%CI:0.44-1.48, p=0.49). Adjustment of additional confounders after stratification by propensity quintiles did not change results. Propensity matching resulted in 1,658 TNFI, 829 nBio and 829 nTNFi. The HZ rate in the matched cohorts was 9/1000 person yrs [95% CI: 6, 11]. Results are presented in Table 1 and are similar between the two analytic approaches. Conclusions The rate of HZ was comparable among RA patients initiating TNFi, nTNFi or nBIO DMARDs agents in the CORRONA registry. Disclosure of Interest D. Pappas: None Declared, M. Hooper Shareholder of: Amgen, Employee of: Amgen, G. Reed Grant/Research support from: CORRONA, Consultant for: CORRONA, Employee of: University of Massachusetts Medical School, Paid Instructor for: Harvard Medical School, Y. Shan: None Declared, D. Wenkert Shareholder of: Amgen, Employee of: Amgen, J. Zhang Grant/Research support from: Amgen, J. Greenberg Shareholder of: CORRONA, Consultant for: AstraZeneca, Novartis, Pfizer, CORRONA, J. Curtis Grant/Research support from: NIH (AR053351), AHRQ (R01HS018517), Amgen, UCB, CORRONA, Genentech, Janssen, Pfizer, Crescendo Bioscience, Consultant for: Amgen, UCB, CORRONA, Genentech, Janssen, Pfizer, Crescendo Bioscience
Url:
DOI: 10.1136/annrheumdis-2012-eular.2565
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002007
- to stream Istex, to step Curation: 002007
- to stream Istex, to step Checkpoint: 000268
- to stream Main, to step Merge: 001217
- to stream Main, to step Curation: 001216
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">FRI0108 Risk for herpes zoster after treatment with biologic and synthetic disease modifying agents for rheumatoid arthritis</title>
<author><name sortKey="Pappas, D A" sort="Pappas, D A" uniqKey="Pappas D" first="D. A." last="Pappas">D. A. Pappas</name>
</author>
<author><name sortKey="Hooper, M" sort="Hooper, M" uniqKey="Hooper M" first="M." last="Hooper">M. Hooper</name>
</author>
<author><name sortKey="Reed, G" sort="Reed, G" uniqKey="Reed G" first="G." last="Reed">G. Reed</name>
</author>
<author><name sortKey="Shan, Y" sort="Shan, Y" uniqKey="Shan Y" first="Y." last="Shan">Y. Shan</name>
</author>
<author><name sortKey="Wenkert, D" sort="Wenkert, D" uniqKey="Wenkert D" first="D." last="Wenkert">D. Wenkert</name>
</author>
<author><name sortKey="Zhang, J" sort="Zhang, J" uniqKey="Zhang J" first="J." last="Zhang">J. Zhang</name>
</author>
<author><name sortKey="Greenberg, J" sort="Greenberg, J" uniqKey="Greenberg J" first="J." last="Greenberg">J. Greenberg</name>
</author>
<author><name sortKey="Curtis, J" sort="Curtis, J" uniqKey="Curtis J" first="J." last="Curtis">J. Curtis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C2D6BD857D3E9D8926749C73539233ABD6C47B63</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2012-eular.2565</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-KSNFFCKP-T/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002007</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002007</idno>
<idno type="wicri:Area/Istex/Curation">002007</idno>
<idno type="wicri:Area/Istex/Checkpoint">000268</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000268</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Pappas D:fri:risk:for</idno>
<idno type="wicri:Area/Main/Merge">001217</idno>
<idno type="wicri:Area/Main/Curation">001216</idno>
<idno type="wicri:Area/Main/Exploration">001216</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">FRI0108 Risk for herpes zoster after treatment with biologic and synthetic disease modifying agents for rheumatoid arthritis</title>
<author><name sortKey="Pappas, D A" sort="Pappas, D A" uniqKey="Pappas D" first="D. A." last="Pappas">D. A. Pappas</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Columbia University</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Columbia University</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hooper, M" sort="Hooper, M" uniqKey="Hooper M" first="M." last="Hooper">M. Hooper</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Oaks</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Reed, G" sort="Reed, G" uniqKey="Reed G" first="G." last="Reed">G. Reed</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Shan, Y" sort="Shan, Y" uniqKey="Shan Y" first="Y." last="Shan">Y. Shan</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Worcester</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Wenkert, D" sort="Wenkert, D" uniqKey="Wenkert D" first="D." last="Wenkert">D. Wenkert</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Oaks</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Zhang, J" sort="Zhang, J" uniqKey="Zhang J" first="J." last="Zhang">J. Zhang</name>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
<wicri:orgArea>University of Alabama at Birmingham</wicri:orgArea>
</affiliation>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
<wicri:orgArea>University of Alabama at Birmingham</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Greenberg, J" sort="Greenberg, J" uniqKey="Greenberg J" first="J." last="Greenberg">J. Greenberg</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>NYU Langone Medical School, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>NYU Langone Medical School, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Curtis, J" sort="Curtis, J" uniqKey="Curtis J" first="J." last="Curtis">J. Curtis</name>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
<wicri:orgArea>University of Alabama at Birmingham</wicri:orgArea>
</affiliation>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
<wicri:orgArea>University of Alabama at Birmingham</wicri:orgArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">71</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="346">346</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Additional confounders</term>
<term>Amgen</term>
<term>Biologic</term>
<term>Brosis</term>
<term>Cardiovascular</term>
<term>Cardiovascular disease</term>
<term>Cholesterol levels</term>
<term>Cohort</term>
<term>Corrona</term>
<term>Corrona registry</term>
<term>Crescendo bioscience</term>
<term>Echographic</term>
<term>Expert physician</term>
<term>Herpes zoster</term>
<term>Hrct</term>
<term>Hrct scores</term>
<term>Lung ultrasound</term>
<term>Nbio</term>
<term>Nijmegen</term>
<term>Ntnfi</term>
<term>Ntnfi cohort</term>
<term>Propensity</term>
<term>Propensity score</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Serum samples</term>
<term>Tnfi</term>
<term>Tnfi cohort</term>
<term>Total number</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background Herpes zoster (HZ) is an opportunistic infection with a high incidence in Rheumatoid Arthritis (RA) patients. There are contradictory data regarding the risk of HZ associated with treatment with biologic and non biologic disease modifying agents (DMARD). Objectives To compared the risk for HZ among new users of TNF inhibitors (TNFi), non-TNF inhibitor biologics (nTNFi) and non biologic DMARD (nBIO) in RA patients participating in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Methods The CORRONA registry is a network of rheumatology practices across the U.S. with patient and physician derived data on more than 27,000 RA patients. Patients with or without background methotrexate were categorized to three treatment cohorts (TNFi vs nTNFi vs nBIO). Follow-up time began with initiation of a TNFi; a nTNFi; or Leflunomide, sulfasalazine, or hydroxychloroquine (nBIO cohort). Exposure was considered “as treated” and analyses were censored if patients switched treatment groups and after the 1st HZ event. HZ events were based on physician report. Patients with a history of HZ were excluded (analysis without their exclusion yielded similar results). Propensity scores (PS) were created using multinomial logistic regression, and the PS included age, gender, prednisone use, mHAQ, CDAI, duration of RA, Rheumatoid factor positivity (RF+), history of diabetes mellitus (DM) cardiovascular disease (CVD) and cancer (Ca). Stratification on propensity score quintile was conducted and hazard ratios (HR) were estimated using Cox regression to examine the risk of HZ associated with each treatment. Any factors in imbalance within stratified quintiles were examined as additional confounders. In a separate analysis, three way propensity score matching of nBIO, TNFi, and nTNFi biologic (1:2:1) was performed with a propensity score using age, gender, prednisone treatment (tx), mHAQ, duration of RA, and RF+. Results The propensity stratified analysis included 2,809 in the TNFi cohort, 1,182 in the nTNFi cohort and 1,070 in the nBIO 842 cohort. At baseline: the nTNFi cohort included more females, patients with longer RA duration, more frequent RF+ and steroid tx, higher mHAQ, and CDAI. The TNF cohort included younger patients with fewer comorbidities (DM, Ca, CVD). The overall rate of HZ was 8/1000 person yrs [95%CI: 7, 11]. Using the TNFi cohort as the referent group the hazard ratio for nBIO was 0.97 (95%CI:0.54-1.77, p=0.93) and for nTNFi was 0.81 (95%CI:0.44-1.48, p=0.49). Adjustment of additional confounders after stratification by propensity quintiles did not change results. Propensity matching resulted in 1,658 TNFI, 829 nBio and 829 nTNFi. The HZ rate in the matched cohorts was 9/1000 person yrs [95% CI: 6, 11]. Results are presented in Table 1 and are similar between the two analytic approaches. Conclusions The rate of HZ was comparable among RA patients initiating TNFi, nTNFi or nBIO DMARDs agents in the CORRONA registry. Disclosure of Interest D. Pappas: None Declared, M. Hooper Shareholder of: Amgen, Employee of: Amgen, G. Reed Grant/Research support from: CORRONA, Consultant for: CORRONA, Employee of: University of Massachusetts Medical School, Paid Instructor for: Harvard Medical School, Y. Shan: None Declared, D. Wenkert Shareholder of: Amgen, Employee of: Amgen, J. Zhang Grant/Research support from: Amgen, J. Greenberg Shareholder of: CORRONA, Consultant for: AstraZeneca, Novartis, Pfizer, CORRONA, J. Curtis Grant/Research support from: NIH (AR053351), AHRQ (R01HS018517), Amgen, UCB, CORRONA, Genentech, Janssen, Pfizer, Crescendo Bioscience, Consultant for: Amgen, UCB, CORRONA, Genentech, Janssen, Pfizer, Crescendo Bioscience</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Midlands de l'Ouest</li>
<li>État de New York</li>
</region>
<settlement><li>Birmingham</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Hooper, M" sort="Hooper, M" uniqKey="Hooper M" first="M." last="Hooper">M. Hooper</name>
<name sortKey="Reed, G" sort="Reed, G" uniqKey="Reed G" first="G." last="Reed">G. Reed</name>
<name sortKey="Shan, Y" sort="Shan, Y" uniqKey="Shan Y" first="Y." last="Shan">Y. Shan</name>
<name sortKey="Wenkert, D" sort="Wenkert, D" uniqKey="Wenkert D" first="D." last="Wenkert">D. Wenkert</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Pappas, D A" sort="Pappas, D A" uniqKey="Pappas D" first="D. A." last="Pappas">D. A. Pappas</name>
</region>
<name sortKey="Greenberg, J" sort="Greenberg, J" uniqKey="Greenberg J" first="J." last="Greenberg">J. Greenberg</name>
<name sortKey="Greenberg, J" sort="Greenberg, J" uniqKey="Greenberg J" first="J." last="Greenberg">J. Greenberg</name>
<name sortKey="Pappas, D A" sort="Pappas, D A" uniqKey="Pappas D" first="D. A." last="Pappas">D. A. Pappas</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Zhang, J" sort="Zhang, J" uniqKey="Zhang J" first="J." last="Zhang">J. Zhang</name>
</region>
<name sortKey="Curtis, J" sort="Curtis, J" uniqKey="Curtis J" first="J." last="Curtis">J. Curtis</name>
<name sortKey="Curtis, J" sort="Curtis, J" uniqKey="Curtis J" first="J." last="Curtis">J. Curtis</name>
<name sortKey="Zhang, J" sort="Zhang, J" uniqKey="Zhang J" first="J." last="Zhang">J. Zhang</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001216 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001216 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:C2D6BD857D3E9D8926749C73539233ABD6C47B63 |texte= FRI0108 Risk for herpes zoster after treatment with biologic and synthetic disease modifying agents for rheumatoid arthritis }}
This area was generated with Dilib version V0.6.33. |